SCHEMBL12013151

SCHEMBL12013151

CC(C)COC(C)C(C)C

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12013698 1.00 ALDH1A1 (0.35) ALDH1A1
SCHEMBL16786171 1.00 ALDH1A1 (0.35) ALDH1A1
SCHEMBL6123617 0.89 TDP1 (0.31)
SCHEMBL6620425 0.75
SCHEMBL9730351 0.75 ALDH1A1 (0.32) ALDH1A1
SCHEMBL24554757 0.75 ALDH1A1 (0.32) ALDH1A1
SCHEMBL26043669 0.75 TDP1 (0.43) ALDH1A1
SCHEMBL27646577 0.74 TDP1 (0.42)
SCHEMBL9455726 0.73 ALDH1A1 (0.35) ALDH1A1
SCHEMBL17103148 0.73 MAPT (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577245-B2 Method for purifying phosphoric acid LXP GROUP GMBH (DE) 2020-03-03 US claimed
CN-106103341-B Process for purifying phosphoric acid LXP集团有限公司 2019-07-02 CN claimed
EP-2924003-B1 Method for purifying phosphoric acid LXP GROUP GMBH (DE) 2019-05-08 EP claimed
US-20170081189-A1 METHOD FOR PURIFYING PHOSPHORIC ACID LXP GROUP GMBH (DE) 2017-03-23 US claimed
CN-106103341-A Process for purifying phosphoric acid LXP集团有限公司 2016-11-09 CN claimed
EP-2924003-A1 Method for purifying phosphoric acid Maxbiogas GmbH (DE) 2015-09-30 EP claimed
US-20240067760-A1 COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME HERCULES CAPITAL, INC., AS AGENT 2024-02-29 US disclosed
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease SHY Therapeutics LLC 2023-09-14 US disclosed
US-20230265219-A1 COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
US-20230149369-A1 Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease SHY Therapeutics LLC (US) 2023-05-18 US disclosed
US-10577245-B2 Method for purifying phosphoric acid LXP GROUP GMBH (DE) 2020-03-03 US disclosed
CN-106103341-B Process for purifying phosphoric acid LXP集团有限公司 2019-07-02 CN disclosed
EP-2924003-B1 Method for purifying phosphoric acid LXP GROUP GMBH (DE) 2019-05-08 EP disclosed
CN-100547485-C Photosensitive resin composition AZ ELECTRONIC MATERIALS JAPAN (JP) 2009-10-07 CN disclosed
CN-100535747-C Photosensitive resin composition CLARIANT INT LTD (JP) 2009-09-02 CN disclosed
US-20090208873-A1 POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-08-20 US disclosed
US-20070224540-A1 Positive resist composition and pattern formation method using the same FUJIFILM CORPORATION (JP) 2007-09-27 US disclosed
US-20070072117-A1 Positive resist composition and pattern forming method using the same FUJI PHOTO FILM CO., LTD. 2007-03-29 US disclosed
CN-1816775-A Photosensitive resin composition CLARIANT INT LTD (JP) 2006-08-09 CN disclosed
CN-1806206-A Photosensitive resin composition AZ ELECTRONIC MATERIALS JAPAN (JP) 2006-07-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease MAPK6, MAP3K6, MAPK4 ALDH1A1 2765/4885
US-20230149369-A1 Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease HRAS, KRAS, NRAS ALDH1A1 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.